Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 4, 1997, Pages 421-428

  Baas, H ^a   Beiske, A G ^b   Ghika, J ^c   Jackson, M ^d   Oertel, W H ^e   Poewe, W ^f,g   Ransmayr, G ^f,g  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d RADCLIFFE INFIRMARY   (United Kingdom)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Universitatsklinik fur Neurochirurgie Innsbruck   (Austria)

Author keywords

"Wearing off" phenomenon; Parkinson's disease; Tolcapone

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE; CATECHOL METHYLTRANSFERASE; LEVODOPA; TOLCAPONE; TRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; BIOLOGICAL AVAILABILITY; CATECHOL O-METHYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 0030880324     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.4.421     Document Type: Article

References (30)

1. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders. London, UK: Butterworth, 1982:41-58.
2. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
3. Martilla RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel Dekker, 1987:35-50.
4. Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 1987;13:141-78.
5. LeWitt PA. Treatment strategies for extension of levodopa effect. Neurol Clin 1992;10:511-26.
6. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-17.
7. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;ii:791-5.
8. Goetz CG, Tanner CM, Glanyz RH, Klawans HL. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985;35:749-51.
9. Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of levodopa: clinical and pharmacokinetic observations. Clin Neuropharmacol 1986;9:430-9.
10. Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-12.
11. Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Kaplan LR, Dichgans J, Diener HC, Kennard C, eds. Neurological disorders: cause and treatment. San Diego: Academic Press, 1996:715-72.
12. Reilly DK, Rivera-Calimlim L, van Dyke D. Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 1980;28:278-86.
13. Da Prada M, Keller HH, Pieri L, et al. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984;40:1165-72.
14. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
15. Mannisto PT, Ulmanen I, Lundstrom K, et al. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992;39: 291-350.
16. Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975;17: 131-6.
17. Zurcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990;32:375-80.
18. Da Prada M, Zurcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Adv Behav Biol 1991;39:723-32.
19. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schlappi B, Zurcher G. Ro 40-7592: catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 1991; 16:719-21.
20. Zurcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New development in therapy of Parkinson's disease. Rome, Italy: John Libbey, 1991:37-43.
21. Dingemanse J, Jorga K, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
22. Myllyla W, and the Tolcapone in PD Study Group I (TIPS). Clinical efficacy of tolcapone in L-dopa-treated parkinsonian patients with "wearing-off" phenomenon: a multicenter double-blind study [abstract]. Neurology 1995;45: A276.
23. Dorflinger EE, Rajput AH, Martin W, et al. Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson's disease patients who exhibit end-of-dose wearing-off [abstract]. Neurology 1996;46: A474-5.
24. Cedarbaum JM, Silvestri M. Methods for assessing motor fluctuations in conducting clinical trials of antiparkinson agents. In: Clifford-Rose F, ed. Parkinson's disease and the problem of clinical trials. London: Smith-Gordon, 1992:75-85.
25. Kurth MC, Adler CH, Saint Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-7.
26. Dingemanse J, Jorga K, Zurcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
27. Bergner M, Bobbitt RA, Carter WB, Gilson SB. The sickness impact profile: development and final revision of a health status measure. Medical Care 1981;19:787-805.
28. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in parkinson's patients taking L-dihydroxyphenylalanine/ carbidopa and selegiline. Mov Disord 1995;10:349-51.
29. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-8.
30. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.